LCTX Projected Dividend Yield
Lineage Cell Therapeutics Inc ( AMEX : LCTX )Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix. 20 YEAR PERFORMANCE RESULTS |
LCTX Dividend History Detail LCTX Dividend News LCTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |